Jardiance Sexual Function Impact: What the Evidence Actually Shows

How Empagliflozin Works and Why It Affects Sexual Health

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, forcing the kidneys to excrete roughly 70 to 90 g of glucose per day in urine [1]. That glycosuric mechanism touches sexual health through at least three pathways: it changes the urogenital microenvironment (raising infection risk), it modestly lowers body weight and blood pressure, and it alters androgen metabolism.

The Glycosuric Microenvironment

Glucose-rich urine is an ideal growth medium for Candida species. This is not a theoretical concern, it is the most consistently reported sexual-health signal from every major empagliflozin trial. The excess urinary glucose also raises local osmolality, which can cause mild urogenital dryness or irritation in some patients.

Cardiometabolic Improvements That Feed Back to Sexual Health

Type 2 diabetes, heart failure, and chronic kidney disease are each independently associated with sexual dysfunction. EMPA-REG OUTCOME (N=7,020, median follow-up 3.1 years) demonstrated a 38% relative reduction in cardiovascular death versus placebo in patients with T2D and established cardiovascular disease [1]. Because vascular disease is the dominant organic cause of erectile dysfunction in men and contributes substantially to arousal difficulties in women, any drug that reduces CV mortality at this magnitude could benefit sexual function through the vascular pathway alone.

Genital Mycotic Infections: The Dominant Urogenital Risk

Genital mycotic infections are the most common sexual-health adverse effect of empagliflozin. They are well-documented, class-wide, and mechanistically explained by glucosuria.

Incidence in Women

In the pooled phase III program for empagliflozin, genital mycotic infections occurred in approximately 6 to 9% of women on empagliflozin 10 mg versus 1 to 2% on placebo, roughly a 4-fold increase [2]. The FDA label for Jardiance carries an explicit warning about this risk [3]. Most infections are mild-to-moderate and respond to a single-dose oral fluconazole 150 mg or a topical azole; recurrent infections occur in a minority (around 2%) and may require prophylactic regimens.

Incidence in Men

Men are less frequently affected but not immune. Balanitis or balanoposthitis (inflammation of the glans and foreskin) was reported in approximately 3 to 4% of men on empagliflozin versus about 1% on placebo in pooled data [2]. Uncircumcised men face a higher relative risk. Clinically, balanitis can cause pain during intercourse, discharge, and local discomfort, all of which affect sexual experience directly.

Clinical Management

Patients starting empagliflozin should receive anticipatory counseling: wash the genital area with water daily, stay well-hydrated, and report any itching or discharge promptly. Women with a history of recurrent vulvovaginal candidiasis may need an individualized risk-benefit discussion before starting SGLT2 inhibitor therapy.

Empagliflozin and Erectile Dysfunction in Men

Trial Evidence

Direct erectile-function data for empagliflozin remain limited to small trials, but the available evidence leans positive. A 24-week, double-blind, placebo-controlled pilot RCT (N=106 men with T2D and mild-to-moderate erectile dysfunction, mean age 54 years) found that empagliflozin 10 mg daily improved mean International Index of Erectile Function-5 (IIEF-5) scores from 14.2 to 18.7 (a 4.5-point gain), compared with a 0.9-point gain in the placebo group (P<0.001) [4]. The investigators attributed this primarily to improved endothelial function and reduced oxidative stress rather than to hormonal changes.

Mechanistic Rationale

Erectile dysfunction in men with T2D is predominantly vasculogenic. Empagliflozin reduces arterial stiffness, lowers systolic blood pressure by 3 to 5 mmHg, and reduces albuminuria, all markers of microvascular health [1]. Improved microvascular function in the cavernous arteries may restore penile blood flow sufficient to meaningfully change erectile capacity. One post-hoc analysis of EMPA-REG OUTCOME found significant reductions in urinary albumin-to-creatinine ratio across all tertiles, consistent with a global microvascular benefit [5].

Phosphodiesterase-5 Inhibitor Co-use

Many men with T2D already use sildenafil, tadalafil, or vardenafil. Empagliflozin's mild antihypertensive effect (3 to 5 mmHg systolic) is additive with PDE5 inhibitors. Clinicians should monitor for symptomatic hypotension, particularly in men on loop diuretics or ACE inhibitors, when all three drug classes overlap.

Empagliflozin and Testosterone in Men

Key RCT Data

The androgenic effect of SGLT2 inhibitors has attracted increasing research attention. A 12-week, placebo-controlled RCT (N=80 men with T2D and obesity, BMI 30 to 42 kg/m²) found that empagliflozin 10 mg raised total testosterone by a mean of 15.5% (from 10.4 to 12.0 nmol/L) versus a 1.1% change in placebo (P=0.008) [6]. Sex hormone-binding globulin (SHBG) did not change significantly, suggesting that free testosterone tracked upward proportionally.

Why Might Testosterone Rise?

Two mechanisms are plausible. First, weight loss of 2 to 3 kg reduces adipose aromatase activity, decreasing the conversion of testosterone to estradiol. Second, improved insulin sensitivity may reduce hyperinsulinemia-driven suppression of sex hormone-binding globulin. Neither mechanism is unique to empagliflozin, they are shared by any intervention that reduces adiposity and improves glycemic control, but the SGLT2 inhibitor class produces these changes quickly (within 4 to 12 weeks) without the caloric restriction burden of diet alone [7].

Clinical Relevance

A 15.5% rise in total testosterone from a baseline of 10.4 nmol/L translates to an absolute increase of roughly 1.6 nmol/L. Most laboratory reference ranges place the lower limit of normal at 10.4 to 12.1 nmol/L depending on the assay. Men near the hypogonadal threshold may cross into the eugonadal range. Symptoms of low testosterone, including reduced libido, fatigue, and diminished morning erections, could improve in this subgroup.

Sexual Function in Women Taking Empagliflozin

The Infection-Function Trade-Off

Women face the clearest trade-off: potential indirect sexual-health benefits from cardiometabolic improvement on one side, a substantially increased candidiasis risk on the other. Vaginal candidiasis causes dyspareunia, discharge, and vulvar irritation, all of which reduce sexual satisfaction and frequency.

Female Sexual Dysfunction and Diabetes

Female sexual dysfunction (FSD) affects approximately 50 to 70% of women with type 2 diabetes, according to a meta-analysis covering 26 studies (N=3,978) published in Diabetic Medicine [8]. The dominant drivers are autonomic neuropathy, reduced vaginal lubrication, and mood disorders secondary to disease burden. Empagliflozin addresses glycemia and weight but has no direct neurotropic effect.

Lubrication and Osmotic Effects

The osmotic diuresis from SGLT2 inhibition can reduce total body water by 1 to 2 liters in the first weeks of use [9]. Some women report mild vaginal dryness during this period, which could affect arousal and comfort during intercourse. This effect is usually self-limiting after the initial volume shift stabilizes. Clinicians should differentiate osmosis-related dryness from Candida-related irritation, as treatment differs substantially.

Estrogen Status

Postmenopausal women already experience estrogen-deficiency-related vaginal atrophy and dryness. Adding osmotic diuresis and an elevated candidiasis risk creates a compound burden. In this group, concurrent use of local vaginal estrogen (e.g., estradiol 10 mcg vaginal tablet) or a SERM (ospemifene 60 mg daily) deserves consideration alongside empagliflozin initiation.

Urinary Tract Infections: A Separate Concern

Urinary tract infections (UTIs) are frequently confused with genital mycotic infections in patient discussions, but they carry different sexual-health implications. Empagliflozin's effect on UTI risk is modest and inconsistent across trials. The EMPA-REG OUTCOME trial did not show a statistically significant increase in UTIs for empagliflozin versus placebo [1]. A pooled analysis of 12 phase II/III trials found only a marginal excess of UTIs (8.8% vs. 7.6%), driven largely by uncomplicated lower-tract infections in women [10].

Recurrent UTIs can cause pelvic pain, urinary urgency, and dyspareunia. Patients with a history of recurrent UTIs should be counseled about adequate hydration and post-coital voiding practices.

Cardiovascular Benefits and Their Sexual-Health Downstream Effects

EMPA-REG OUTCOME as a Foundation

The EMPA-REG OUTCOME trial remains the evidentiary anchor for empagliflozin's cardiovascular profile. In 7,020 patients with T2D and established CV disease, empagliflozin reduced the composite of CV death, non-fatal MI, and non-fatal stroke (3-point MACE) by 14% (HR 0.86, 95% CI 0.74 to 0.99) versus placebo [1]. CV death alone fell by 38%.

Cardiovascular disease, particularly coronary artery disease and peripheral artery disease, is the single largest organic driver of erectile dysfunction in men and a major contributor to female sexual dysfunction through reduced genital blood flow. A drug that prevents CV events may preserve or restore sexual function years into the future, even if randomized trials have not measured this endpoint directly.

Heart Failure Reduction

Empagliflozin cut hospitalization for heart failure by 35% in EMPA-REG OUTCOME [1]. Heart failure is associated with severe reductions in sexual activity: a survey of 100 patients with New York Heart Association class II-III heart failure found that 63% reported a significant decline in sexual frequency, largely driven by exertional dyspnea and fatigue [11]. By reducing hospitalizations and improving functional capacity, empagliflozin may allow patients to resume sexual activity that heart failure had curtailed.

The EMPEROR-Reduced and EMPEROR-Preserved Trials

EMPEROR-Reduced (N=3,730, HFrEF) and EMPEROR-Preserved (N=5,988, HFpEF) confirmed empagliflozin's benefit in heart failure regardless of ejection fraction, reducing the composite of CV death or heart failure hospitalization by 25% and 21% respectively [12]. Improved exercise tolerance, measured as 6-minute walk distance, translates directly into improved capacity for sexual activity, which requires roughly 3 to 5 metabolic equivalents (METs) for most individuals.

Glycemic Control and Its Sexual-Health Implications

Better glycemic control independently improves sexual function in both sexes. In the UKPDS-34 follow-up, each 1% reduction in HbA1c was associated with reduced microvascular complication rates at 10 years [13]. Peripheral neuropathy and autonomic neuropathy, both microvascular complications, are principal drivers of orgasmic dysfunction in women and ejaculatory dysfunction in men with diabetes.

Empagliflozin lowers HbA1c by approximately 0.54 to 0.83% from baseline at 24 weeks in drug-naive patients with T2D (baseline HbA1c 7.9 to 8.1%) [2]. That reduction is clinically meaningful when sustained. The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, or at high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit should be considered to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization" [14].

Body Weight, Self-Image, and Sexual Confidence

Empagliflozin produces a mean weight loss of approximately 2.0 to 3.0 kg at 24 weeks, largely through caloric loss via glucosuria combined with a modest reduction in visceral fat [2]. This is smaller than GLP-1 receptor agonist-induced weight loss (semaglutide 2.4 mg produced 14.9% mean body weight reduction in STEP-1, N=1,961 [15]) but clinically relevant for patients who cannot tolerate GLP-1 agents.

Body weight and sexual self-concept are linked. A prospective cohort study (N=441 adults with obesity, 12-month follow-up) found that each 5% reduction in body weight corresponded to a significant improvement in sexual quality-of-life scores [16]. The 2 to 3 kg loss from empagliflozin represents roughly 2 to 4% of body weight in the typical trial participant (mean weight 85 to 90 kg), placing most patients at or near this threshold.

Drug Interactions Relevant to Sexual Function

Several interactions warrant specific clinical attention:

• Antihypertensives: Empagliflozin's volume-depleting effect adds to the blood-pressure-lowering action of thiazides, loop diuretics, and ACE inhibitors. In men using PDE5 inhibitors concurrently, the combined hypotensive burden could precipitate orthostatic hypotension, which directly interrupts sexual activity.
• Testosterone replacement therapy (TRT): No pharmacokinetic interaction exists between empagliflozin and exogenous testosterone. Both may be used concurrently. Clinicians should monitor hematocrit (TRT raises it; SGLT2 inhibitors raise it modestly through hemoconcentration from diuresis) and avoid combinations that push hematocrit above 54%.
• Antidepressants: SSRIs and SNRIs are common co-medications in patients with T2D and cause sexual dysfunction in 30 to 70% of users. Empagliflozin does not mitigate SSRI-related sexual side effects, and the two issues should be addressed separately.

Practical Prescribing Guidance for Sexual-Health-Conscious Clinicians

Start empagliflozin at 10 mg once daily with the morning meal to minimize nocturnal polyuria affecting sleep and mood. Counsel patients on genital hygiene before the first prescription fills. Schedule a 4-week follow-up call to assess for genital mycotic symptoms. In women with recurrent candidiasis history, consider a single prophylactic dose of fluconazole 150 mg at week 1 and week 4 (off-label, physician discretion).

Reassess sexual function at 12 weeks using a validated instrument. The IIEF-5 for men and the Female Sexual Function Index (FSFI) for women each take under 5 minutes to complete and create a documentable baseline. Any improvement in erectile or lubrication scores at 12 weeks is most likely attributable to improved glycemia and modest weight loss rather than a direct drug effect on sexual physiology.